EP3645119A1 - Veterinary granules composition containing hemp extract - Google Patents

Veterinary granules composition containing hemp extract

Info

Publication number
EP3645119A1
EP3645119A1 EP18746743.6A EP18746743A EP3645119A1 EP 3645119 A1 EP3645119 A1 EP 3645119A1 EP 18746743 A EP18746743 A EP 18746743A EP 3645119 A1 EP3645119 A1 EP 3645119A1
Authority
EP
European Patent Office
Prior art keywords
dietary supplement
veterinary composition
cannabinoids
hemp
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18746743.6A
Other languages
German (de)
French (fr)
Inventor
Miriam HALPERIN WERNLI
Jorge WERNLI
Gian Batista TREPP
Silvia Huber
Franco MADEA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creso Pharma Switzerland GmbH
Original Assignee
Creso Pharma Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creso Pharma Switzerland GmbH filed Critical Creso Pharma Switzerland GmbH
Publication of EP3645119A1 publication Critical patent/EP3645119A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the invention pertains to veterinary compositions or dietary or feed supplements for use in the prevention or the treatment of behavioral, respectively age-related disorders or troubles in mammals, or for supporting or strengthening the immune system, the behavioral balance of mammals and for supporting the natural inflammatory response of mammals, in particular of companion animals.
  • THC toxicity can be serious and prevent the pet from standing and eating , so overdosage can be counterproductive if not dangerous.
  • compositions making use of hemp or cannabis oils or extracts used as the source of cannabinoids wherein the amount of active substances is easier to control.
  • Such compositions are frequently provided in their liquid, in particular oily form or as capsules which, however, necessitates a very cautious administration.
  • Oils or capsules do not dissolve in the pet mouth and consequently are furthermore subject to significant liver first-pass metabolism as the oral bioavailability of cannabinoids is below In certain cases, an adequate mixing to the pet diet is also of concern, especially when off flavors are too intense and then cause rejection of the diet provided to the pet.
  • composition according to the invention consist in a veterinary composition or dietary supplement or complementary feed which is in the form of water soluble polysaccharide-based granules comprising as the source of cannabinoids as a standardized oil or a standardized extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
  • mammals define here companion animals like dogs, cats, horses, donkeys and mules and camels or zoo animals where behavioral disorders like anxiety, stress or seizures are frequently of concern.
  • granules defines here edible particles in their granulated form, e.g. such as spherical or similar particles consisting essentially of a water soluble biodegradable matrix containing the selected active substances, wherein the cannabinoids providing from hemp or cannabis extract are dispersed inside or sprayed or coated on the surface.
  • these granules can further comprise additives like stabilizers, binding or disintegrating agents or even flavors.
  • the granules of the invention can be prepared according to the techniques conventional in the art such as extrusion, nebulization or fluid-bed granulation.
  • polysaccharides defines substances commonly used in veterinary or human medicine as carriers and more particularly water-soluble polysaccharides selected among starch, soluble starch, microcrystalline cellulose, dextrin, dextrose, sucrose, isomaltose, oligosaccharides such as fructo-oligosaccharides (FOS) or gluco-oligosaccharides (GOS), mixtures of same and any other water-soluble representatives of this class of compounds. This enumeration, however, is not limitative.
  • the term "essentially devoid of” defines here cannabis or hemp (Cannabis sativa L.) oils or extracts wherein the content of psychotropic substances, namely THC is significantly below the applicable regulatory provisions according to EFSA and EU regulatory bodies
  • standardized oil and "standardized extract” apply to compositions of matter that are either already commercially available or manufactured on request by dedicated companies that are mastering current extraction, e.g. solvent or C02 extraction, and purification techniques and that can deliver oils or extracts with a precisely defined and characterized content in active substances, cannabinoids in the instant case.
  • Standardized hemp (Cannabis sativa L.) extracts used according to the invention present furthermore a high content in non-psychotropic cannabinoids and in particular CBD, namely up to ca. 25 to 50 or even 80 % CBD and with THC less than 0.05 % (weight).
  • An example of a preferred standardized hemp extract comprises 23.6 % CBD, 0.25 % of a mix of CBDV, CBDA & CBG and less than 0.05 % THC (weight).
  • the selected hemp extract is defined as "full spectrum” extract, meaning that it contains a blend of other cannabinoids, terpenes, flavonoids and phytonutrients that boost its bioavailability.
  • the granule composition according to the invention has been conceived to be delivered through a delivery system which maximizes the absorption and the bioavailability to optimize the benefits of the hemp oils extract, in particular the cannabinoids contained therein, essentially CBD and any additional active ingredients.
  • the active ingredients are delivered through granules, which are highly soluble in saliva of the mouth and in water. While oils or capsules do not dissolve in saliva or water and have to go through the gastro-intestinal tract, the active ingredients, namely the cannabinoids, are diffused directly into the blood vessels in the mouth through buccal diffusion.
  • the granule composition according to the invention absorbs straight into the pet's blood through the mucosal membrane in the mouth, allowing the hemp components, i.e. the cannabinoids, mainly CBD here, to bypass the gastrointestinal system and the first pass liver metabolism.
  • the effect is likely as high as 30 % versus 4 to 6 % of that observed when cannabinoids are administered by means of oils.
  • buccal absorption provides a more precise dosing.
  • Veterinary compositions or dietary supplements according to the invention are conveniently used by simple addition or mixing with the regular diet of the selected mammal, e.g. the selected companion animal (pet).
  • the administration follows usually the same feeding pattern as that applied for healthy pets, e.g. once or twice a day. Although this way of administration is preferred, pouring directly granules according to the invention into the pet's mouth is also accepted and even common practice.
  • the dosage of CBD i.e. the main active cannabinoid
  • the dosage of CBD extends conveniently from ca. 0.2 to 10, preferably from 0.2 to 5 mg per day per kg body weight.
  • the prevention of said troubles or disorders requires low 0.2 to 0.5 mg CBD per day per kg body weight.
  • the advice is to start low and increase slowly. Due to the lack of THC negative side effects or even drug addiction are definitely avoided.
  • Severe troubles may require significantly higher dosages over a shortened period, e.g. ca. 10 to 25 mg CBD per day per kg body weight or even more. But even at these doses no negative side effects are predicted as well as any addiction.
  • the veterinary composition or dietary supplement according to the invention can be provided in the form of unit doses each corresponding to one serving as follows: for dogs, sachets, pouches or bags or capsules containing 5 g of granules comprising 10 mg of the hemp (Cannabis sativa L.) extract mentioned here above or, expressed differently 2.0 to 3.0 mg CBD;
  • dogs weighing from 5 to 20 kg are conveniently treated by means of one portion of 5 g granules per day whereas dogs with body weight over that 20 kg are conveniently treated with 3 portions of 5 g per day or even more if ever necessary.
  • sachets containing granules providing up to 8 mg CBD par dose can be used within that frame.
  • horses weighing less than 500 kg are usually provided with one 16 g portion of granules per day which is most frequently administered directly into the mouth, whereas horses weighing more than 500 kg are usually provided with two 16 g doses of granules per day or even more if ever necessary.
  • Camels or zoo animals can be subject to similar dosages as long as the above ratio CBD per day per kg body weight is duly monitored.
  • sucrose 41 % weight
  • dextrose D-glucose monohydrate 58 %
  • glucose syrup 1.4 % weight
  • Micronutrients like Vitamin B6, Niacin and zinc acetate dihydrate can be added to the above formulation if ever desired; the latter can further comprise a stabilizer like gum Arabic or similar. Portions of 5 g granules were then packed individually to afford dose units providing each ca. 10.5 mg hemp extract** corresponding to ca. 2.5 mg CBD per 5 g portion.
  • Portions of 16 granules each manufactured according to the method of Example 1 have been prepared in such a way to comprise 360 to 370 mg of the above hemp extract** or, expressed differently ca. 80 mg CBD per 16 portions.
  • the latter are designed for large mammals like horses, camel and zoo animals.
  • CBD 0.25 % weight (CBDV + CBDA + CBG) and less that 0.05 % weight THC.
  • a sugar-free granule composition was prepared according to Example 1 when substituting the 41 % weight of sucrose by 20 % weight of GOS/FOS and the necessary increase of weight % of dextrose to balance.
  • Such a granule formulation has the advantage to be less caloric and consequently better suited to dogs suffering from age related disorders or diseases like diabetes.
  • This granule formulation is also better suited for treating chronic pain over an extended period.
  • the proportions of dextrose can vary from 30 to 90 % of weight without affecting substantially the delivery of the cannabinoids provided by the hemp extract.
  • sucrose the proportions of which can vary from 10 to 70 % weight whereas those of GOS/FOS are kept between 10 and 20 % weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Cette invention concerne des compositions vétérinaires ou des compléments diététiques ou alimentaires utiles dans la prévention ou le traitement des troubles du comportement, respectivement liés à l'âge, et de la douleur chez les mammifères. Ils sont également destinés à soutenir ou à renforcer le système immunitaire, le bilan comportemental des mammifères et à soutenir la réponse inflammatoire naturelle. Ces compositions ou compléments se présentent sous la forme de granulés hydrosolubles à base de polysaccharides qui contiennent à titre de source de cannabinoïdes une huile normalisée ou un extrait de chanvre (Cannabis sativa L.) sensiblement dépourvu de substances psychotropes.This invention relates to veterinary compositions or dietary or dietary supplements useful in the prevention or treatment of age-related behavioral disorders and mammalian pain. They are also intended to support or strengthen the immune system, the behavioral balance of mammals and to support the natural inflammatory response. These compositions or supplements are in the form of water-soluble granules based on polysaccharides which contain as a source of cannabinoids a standardized oil or hemp extract (Cannabis sativa L.) substantially free of psychotropic substances.

Description

Veterinary granules composition containing hemp extract
The invention pertains to veterinary compositions or dietary or feed supplements for use in the prevention or the treatment of behavioral, respectively age-related disorders or troubles in mammals, or for supporting or strengthening the immune system, the behavioral balance of mammals and for supporting the natural inflammatory response of mammals, in particular of companion animals.
Background of the invention
There exist already a few veterinary products comprising cannabinoids and which have been proposed for preventing or treating behavioral troubles affecting pets or companion animals, mainly dogs, cats and horses.
They are provided in various forms like treats, croquettes or biscuits comprising hemp or cannabis plant material intimately mixed with a suitable carrier. Although the relevant plant material can be controlled more or less efficiently in terms of concentration of active substances, i.e. the cannabinoids, administration of same can be problematic if dosage is not duly monitored.
This is particularly true if minor quantities of psychotropic substances like e.g. THC or are still present: THC toxicity can be serious and prevent the pet from standing and eating , so overdosage can be counterproductive if not dangerous.
There also exist veterinary compositions making use of hemp or cannabis oils or extracts used as the source of cannabinoids wherein the amount of active substances is easier to control. Such compositions are frequently provided in their liquid, in particular oily form or as capsules which, however, necessitates a very cautious administration.
For instance, a few more drops only per body weight, can lead to undesired effects due to their high concentration of cannabinoids and namely psychotropic THC even when the latter is only present as traces. In that context too, THC toxicity can be serious and prevent the pet from standing and eating.
Oils or capsules do not dissolve in the pet mouth and consequently are furthermore subject to significant liver first-pass metabolism as the oral bioavailability of cannabinoids is below In certain cases, an adequate mixing to the pet diet is also of concern, especially when off flavors are too intense and then cause rejection of the diet provided to the pet.
There is today an imperious need to obviate and to overcome efficiently all the above-mentioned drawbacks when providing to the pets in need thereof new and easily absorbed veterinary compositions comprising hemp extracts. This goal is achieved by means of the invention defined below.
The invention
The composition according to the invention consist in a veterinary composition or dietary supplement or complementary feed which is in the form of water soluble polysaccharide-based granules comprising as the source of cannabinoids as a standardized oil or a standardized extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
The latter is designed for a wide scope of uses and in particular in:
- the prevention or the treatment of behavioral disorders or troubles in mammals
- the prevention or the treatment of age related disorders or troubles in mammals
- supporting or strengthening the behavioral balance of mammals
- the prevention or the treatment of pain or inflammation in mammals
- supporting and strengthening the immune system and the natural anti-inflammatory response in mammals
and even more, in fact almost any troubles and disorders that can be therapeutically addressed in animals by means of the administration of cannabis- or hemp derived extracts with non-psychotropic cannabinoids and terpenes.
Definitions
The term "mammals" define here companion animals like dogs, cats, horses, donkeys and mules and camels or zoo animals where behavioral disorders like anxiety, stress or seizures are frequently of concern.
The term "granules" defines here edible particles in their granulated form, e.g. such as spherical or similar particles consisting essentially of a water soluble biodegradable matrix containing the selected active substances, wherein the cannabinoids providing from hemp or cannabis extract are dispersed inside or sprayed or coated on the surface. In certain cases, these granules can further comprise additives like stabilizers, binding or disintegrating agents or even flavors. The granules of the invention can be prepared according to the techniques conventional in the art such as extrusion, nebulization or fluid-bed granulation. The term "polysaccharides" defines substances commonly used in veterinary or human medicine as carriers and more particularly water-soluble polysaccharides selected among starch, soluble starch, microcrystalline cellulose, dextrin, dextrose, sucrose, isomaltose, oligosaccharides such as fructo-oligosaccharides (FOS) or gluco-oligosaccharides (GOS), mixtures of same and any other water-soluble representatives of this class of compounds. This enumeration, however, is not limitative.
The term "essentially devoid of" defines here cannabis or hemp (Cannabis sativa L.) oils or extracts wherein the content of psychotropic substances, namely THC is significantly below the applicable regulatory provisions according to EFSA and EU regulatory bodies
recommendation to be equal to or lower than 10 ppm (mg per kg), usually below 0.2 % if not below 0.05 % (weight). Some of such oils or extracts are commercially available whereas others can be obtained when subjecting the adequate raw plant material i.e. buds, leaves, flowers, etc. or their oils or their extracts to specific extraction and purification techniques.
The terms "standardized oil" and "standardized extract" apply to compositions of matter that are either already commercially available or manufactured on request by dedicated companies that are mastering current extraction, e.g. solvent or C02 extraction, and purification techniques and that can deliver oils or extracts with a precisely defined and characterized content in active substances, cannabinoids in the instant case.
Standardized hemp (Cannabis sativa L.) extracts used according to the invention present furthermore a high content in non-psychotropic cannabinoids and in particular CBD, namely up to ca. 25 to 50 or even 80 % CBD and with THC less than 0.05 % (weight).
An example of a preferred standardized hemp extract comprises 23.6 % CBD, 0.25 % of a mix of CBDV, CBDA & CBG and less than 0.05 % THC (weight).
According to an optional embodiment of the invention the selected hemp extract is defined as "full spectrum" extract, meaning that it contains a blend of other cannabinoids, terpenes, flavonoids and phytonutrients that boost its bioavailability.
Embodiments of the invention
The granule composition according to the invention has been conceived to be delivered through a delivery system which maximizes the absorption and the bioavailability to optimize the benefits of the hemp oils extract, in particular the cannabinoids contained therein, essentially CBD and any additional active ingredients.
The active ingredients are delivered through granules, which are highly soluble in saliva of the mouth and in water. While oils or capsules do not dissolve in saliva or water and have to go through the gastro-intestinal tract, the active ingredients, namely the cannabinoids, are diffused directly into the blood vessels in the mouth through buccal diffusion.
Within the frame of the invention, it was observed that such a buccal diffusion allows 3 to 4 times higher bioavailability that comparable oral products delivered in an oil or in a capsule.
The granule composition according to the invention absorbs straight into the pet's blood through the mucosal membrane in the mouth, allowing the hemp components, i.e. the cannabinoids, mainly CBD here, to bypass the gastrointestinal system and the first pass liver metabolism. The effect is likely as high as 30 % versus 4 to 6 % of that observed when cannabinoids are administered by means of oils.
Eventually, besides being better absorbed, fast and reliable, buccal absorption provides a more precise dosing.
Veterinary compositions or dietary supplements according to the invention are conveniently used by simple addition or mixing with the regular diet of the selected mammal, e.g. the selected companion animal (pet). The administration follows usually the same feeding pattern as that applied for healthy pets, e.g. once or twice a day. Although this way of administration is preferred, pouring directly granules according to the invention into the pet's mouth is also accepted and even common practice.
For preventing or treating the various troubles or disorders which are addressed within the frame of the invention the dosage of CBD, i.e. the main active cannabinoid, extends conveniently from ca. 0.2 to 10, preferably from 0.2 to 5 mg per day per kg body weight. The prevention of said troubles or disorders requires low 0.2 to 0.5 mg CBD per day per kg body weight. The advice is to start low and increase slowly. Due to the lack of THC negative side effects or even drug addiction are definitely avoided.
Severe troubles may require significantly higher dosages over a shortened period, e.g. ca. 10 to 25 mg CBD per day per kg body weight or even more. But even at these doses no negative side effects are predicted as well as any addiction.
The veterinary composition or dietary supplement according to the invention can be provided in the form of unit doses each corresponding to one serving as follows: for dogs, sachets, pouches or bags or capsules containing 5 g of granules comprising 10 mg of the hemp (Cannabis sativa L.) extract mentioned here above or, expressed differently 2.0 to 3.0 mg CBD;
for horses or camels or zoo animals, pouches or bags or capsules containing 16 g of granules comprising 320 mg of the hemp (Cannabis sativa L.) extract mentioned here above or, expressed differently 80 mg CBD;
dogs weighing from 5 to 20 kg are conveniently treated by means of one portion of 5 g granules per day whereas dogs with body weight over that 20 kg are conveniently treated with 3 portions of 5 g per day or even more if ever necessary. Alternatively, sachets containing granules providing up to 8 mg CBD par dose can be used within that frame.
horses weighing less than 500 kg are usually provided with one 16 g portion of granules per day which is most frequently administered directly into the mouth, whereas horses weighing more than 500 kg are usually provided with two 16 g doses of granules per day or even more if ever necessary.
Adding the said portions to the daily diet of the horses at stake, nevertheless, is also possible. It was observed that treatments ranging for or even over 20 days did not reveal any negative side effects.
Camels or zoo animals can be subject to similar dosages as long as the above ratio CBD per day per kg body weight is duly monitored.
Examples
Example 1
Predefined portions of sucrose (41 % weight), dextrose (D-glucose monohydrate 58 %) and glucose syrup (1.4 % weight) were intimately mixed with minute amounts of a commercially available, standardized hemp extract** and eventually processed according to a standard granulation technique to afford dried spherical granules containing 0.23 g of the said hemp extract** per lOOg granules.
**containing 23.6 % weight CBD; 0.25 % weight (CBDV + CBDA + CBG) and less that 0.05 % weight THC
Micronutrients like Vitamin B6, Niacin and zinc acetate dihydrate can be added to the above formulation if ever desired; the latter can further comprise a stabilizer like gum Arabic or similar. Portions of 5 g granules were then packed individually to afford dose units providing each ca. 10.5 mg hemp extract** corresponding to ca. 2.5 mg CBD per 5 g portion.
These portions are designed for small mammals like dogs and cats and provide the recommended daily serving for an animal subject to behavioral disorders. Depending on the animal or the severity of the disorder, one observes first signs of relaxing within 30 minutes to 2 hours already.
Example 2
Portions of 16 granules each manufactured according to the method of Example 1 have been prepared in such a way to comprise 360 to 370 mg of the above hemp extract** or, expressed differently ca. 80 mg CBD per 16 portions. The latter are designed for large mammals like horses, camel and zoo animals.
♦♦containing 23.6 % weight CBD; 0.25 % weight (CBDV + CBDA + CBG) and less that 0.05 % weight THC.
Example 3
A sugar-free granule composition was prepared according to Example 1 when substituting the 41 % weight of sucrose by 20 % weight of GOS/FOS and the necessary increase of weight % of dextrose to balance.
Such a granule formulation has the advantage to be less caloric and consequently better suited to dogs suffering from age related disorders or diseases like diabetes.
This granule formulation is also better suited for treating chronic pain over an extended period.
Example 4
Referring to the recipe disclosed in Example 1 the proportions of dextrose can vary from 30 to 90 % of weight without affecting substantially the delivery of the cannabinoids provided by the hemp extract.
The same applies concerning sucrose the proportions of which can vary from 10 to 70 % weight whereas those of GOS/FOS are kept between 10 and 20 % weight.

Claims

1. A veterinary composition or dietary supplement for use in the prevention or the treatment of behavioral disorders or troubles in mammals which is in the form of water soluble polysaccharide-based granules comprising as the source of
cannabinoids an oil or an extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
2. A veterinary composition or dietary supplement for use in the prevention or the treatment of age related disorders or troubles in mammals which is in the form of water soluble polysaccharide-based granules comprising as the source of
cannabinoids an oil or an extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
3. A veterinary composition or dietary supplement for use in supporting or
strengthening the behavioral balance of mammals which is in the form of water soluble polysaccharide-based granules comprising as source of cannabinoids an oil or an extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
4. A veterinary composition or dietary supplement for use in the prevention or the treatment of pain or inflammation or nauseas in mammals which is in the form of water soluble polysaccharide-based granules comprising as source of cannabinoids an oil or an extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
5. A veterinary composition or dietary supplement for use in supporting and
strengthening the immune system and the natural anti-inflammatory response in mammals which is in the form of water soluble polysaccharide-based granules comprising as source of cannabinoids an oil or an extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
6. A veterinary composition or dietary supplement according to any of the preceding claims wherein the granules consist of a matrix of water soluble polysaccharides selected among starch, soluble starch, microcrystalline cellulose, dextrin, dextrose, sucrose, isomaltose, oligosaccharides such as fructo-oligosaccharides (FOS) or gluco- oligosaccharides (GOS) and mixtures of same.
7. A veterinary composition or dietary supplement according to any of the preceding claims wherein the source of cannabinoids is a C02 or solvent extract of hemp (cannabis sativa L.) essentially devoid of psychotropic substances and namely devoid of THC.
8. A veterinary composition or dietary supplement according to any of the preceding claims wherein the source of cannabinoids is a standardized solvent extract of hemp (cannabis sativa L.) comprising ca. 25 % (weight) of CBD.
9. A veterinary composition or dietary supplement according to any of the preceding claims wherein the granules comprise ca. 0.01 to 0.25 %, preferably 0.05 to 0.15 % (weight) of CBD.
10. A veterinary composition or dietary supplement according to any of the preceding claims wherein the mammals are zoo animals or companion animals and in particular dogs, cats, horses and camels.
11. A veterinary composition or dietary supplement according to any of the preceding claims which is administered in such a way to provide to the mammals in need thereof a daily dose of ca. 0.1 to 10 mg, preferably ca. 0.5 to 5.0 mg CBD per kg body weight.
EP18746743.6A 2017-06-30 2018-06-25 Veterinary granules composition containing hemp extract Withdrawn EP3645119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527463P 2017-06-30 2017-06-30
PCT/IB2018/000707 WO2019002933A1 (en) 2017-06-30 2018-06-25 Veterinary granules composition containing hemp extract

Publications (1)

Publication Number Publication Date
EP3645119A1 true EP3645119A1 (en) 2020-05-06

Family

ID=63042061

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18746743.6A Withdrawn EP3645119A1 (en) 2017-06-30 2018-06-25 Veterinary granules composition containing hemp extract

Country Status (5)

Country Link
EP (1) EP3645119A1 (en)
BR (1) BR112019026635A2 (en)
CO (1) CO2020000111A2 (en)
MX (1) MX2019015673A (en)
WO (1) WO2019002933A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
CN111978417B (en) * 2019-09-06 2021-08-06 云南汉盟制药有限公司 Extraction method of hemp polysaccharide, product and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007046086A1 (en) * 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Plant extract from THC-poor cannabis for the treatment of diseases
MX395015B (en) * 2014-12-12 2025-03-24 Ojai Energetics Pbc MICROENCAPSULATED COMPOSITIONS OF CANNABINOIDS

Also Published As

Publication number Publication date
WO2019002933A1 (en) 2019-01-03
CO2020000111A2 (en) 2020-01-17
MX2019015673A (en) 2020-02-26
BR112019026635A2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
EP3645119A1 (en) Veterinary granules composition containing hemp extract
JP7597780B2 (en) Cannabis extracts for the treatment of pain, cancer, and epilepsy in animals
JP6092843B2 (en) Composition for the treatment of neurological disorders
CN106255504A (en) Amyotrophy inhibitor containing quercetin glycoside
KR20150103336A (en) Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis
JP2011512342A (en) Combination of vitamin D and 25-hydroxyvitamin D3
WO2023086572A2 (en) Combinations of nanoparticle-encapsulated cargo entities and methods for making and using same
JP2024537890A (en) Cannabis extracts for the treatment of pain, cancer, and epilepsy in animals
CN104394864B (en) Composition containing sesamin, gamma-oryzanol and rice germ oil
US20230056488A1 (en) Composition, article and method for affecting a mammal
Johns et al. Pharmacokinetics of cannabidiol-/cannabidiolic acid-rich hemp oil in juvenile cynomolgus macaques (Macaca fascicularis)
CN101827588B (en) Novel pharmaceutical composition or plant extract containing thymol and/or p-cymene for cognitive function
US20040097429A1 (en) Method for the reduction of the mammalian appetite
EP3042653A1 (en) Clock gene expression level modifier
JPWO2016181945A1 (en) Composition for promoting production of brain-derived neurotrophic factor
EP1317922B1 (en) Antipyretic preparation containing xylitol
EP3206663B1 (en) Cholesterol lowering capsules
JP7610209B2 (en) Composition for improving mitochondrial activity
US11998582B1 (en) Composition for treating bone loss
AU2006347121B2 (en) Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
CN101505774B (en) Composition for the prevention and/or treatment of itching containing a substance derived from the bark of the genus Acacia
CN121313723A (en) A natural camellia oil with blood sugar lowering effects
US20230106523A1 (en) Quercetin enhancement formulation
TW202510892A (en) Combinations for the prevention, improvement and/or treatment of muscle diseases or muscle disorders
TW202434209A (en) Composition containing quercetin or its glycoside for inhibiting or improving renal function reduction

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220104